Publication | Closed Access

The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Pseudomyxoma Peritonei PatientsMedicineSurgical PathologyImmunologyBaseline Inflammatory-based ScoresPathologySerum Tumor MarkersOncologyCancer Research